International Journal of Radiation Oncology*Biology*Physics
Clinical InvestigationInitial Results of a Multicenter Phase 2 Trial of Stereotactic Ablative Radiation Therapy for Oligometastatic Cancer
Introduction
Metastatic cancer has a notoriously poor prognosis, with 5-year survival ranging from 4% to 38% based on tumor location and histology.1 Numerous reports have identified a subset of patients with a limited volume of metastatic disease, termed oligometastatic, who may respond well to aggressive local therapy.2, 3, 4 Because oligometastatic disease has not yet experienced widespread tumor cell dissociation, the sites of tumor burden are limited.5 Aggressive treatment to oligometastatic disease sites could, therefore, decrease tumor burden and provide long-term disease control. Surgical series have demonstrated survival benefits to this approach in numerous cancer types.6, 7, 8, 9 Stereotactic ablative radiation therapy (SABR) consists of high-dose radiation delivered in a highly precise manner.10 SABR allows for excellent local control and limited radiation to surrounding normal tissue. SABR is well tolerated and thus can be performed in patients who are not fit for surgery. Herein we report patient outcomes, toxicity, and quality of life of patients with oligometastatic cancer prospectively treated with SABR.
Section snippets
Patient selection
This was a multicenter prospective phase 2 study evaluating the safety and feasibility of SABR for patients with oligometastatic cancer. Patients included in this analysis were aged ≥18 years and had biopsy-proven oligometastatic or recurrent cancer. Oligometastatic disease was defined as 5 or fewer total sites of metastases in 3 or fewer organs on fluorodeoxyglucose positron emission tomography/computed tomography (CT) scan within 8 weeks of enrollment. Additional eligibility criteria included
Patient and treatment characteristics
From 2011 to 2017, 147 patients were enrolled. The median age at enrollment was 66.4 years (interquartile range, 59.9-74.6) with 51.0% being female. The most common primary tumors included lung (21.8%; non-small cell lung cancer: n = 29; small cell lung cancer: n = 3), colorectal adenocarcinoma (21.1%), head and neck (10.9%, squamous cell carcinoma: n = 11), breast carcinoma (8.8%), and prostate adenocarcinoma (7.5%). The primary lung tumor was treated with a combination of surgery (73.5%),
Discussion
This prospective phase 2 trial investigated the safety and efficacy of SABR for oligometastatic cancer. The oligometastatic state is hypothesized as an interim stage of systemic disease, with a higher potential for durable disease control after aggressive local treatments.2, 4 SABR has generated significant interest in providing localized treatment of oligometastatic lesions. Herein we show SABR to be a safe treatment modality with excellent local control and OS for patients with
Conclusions
This multicenter prospective phase 2 study demonstrates the feasibility and safety of SABR for oligometastatic cancer. This treatment regimen was well tolerated with limited grade 3+ acute and late toxicity and no significant adverse effect on quality of life. Our results demonstrate excellent long-term survival and local control of metastatic sites. Future randomized controlled trials will be needed to definitively determine the role of aggressive local therapy for oligometastatic disease.
References (25)
- et al.
Surgical therapies in brain metastasis
Semin Oncol
(2007) - et al.
Surgical therapy of bone metastases
Semin Oncol
(2007) - et al.
The role of surgery in the management of isolated metastases to the pancreas
Lancet Oncol
(2009) - et al.
Surgical therapy of lung metastases
Semin Oncol
(2007) - et al.
American Society for Therapeutic Radiology and Oncology and American College of Radiology practice guideline for the performance of stereotactic body radiation therapy
Int J Radiat Oncol Biol Phys
(2004) - et al.
Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: Final report of RTOG protocol 90-05
Int J Radiat Oncol Biol Phys
(2000) - et al.
A note on quantifying follow-up in studies of failure time
Control Clin Trials
(1996) - et al.
Oligometastases treated with stereotactic body radiotherapy: Long-term follow-up of prospective study
Int J Radiat Oncol Biol Phys
(2012) - et al.
Progression-free survival following stereotactic body radiotherapy for oligometastatic prostate cancer treatment-naive recurrence: A multi-institutional analysis
Eur Urol
(2016) - et al.
Clinical outcome of stereotactic ablative body radiotherapy for lung metastatic lesions in non-small cell lung cancer oligometastatic patients
Clin Oncol (R Coll Radiol)
(2016)
Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: Long-term results of a prospective phase II trial (Nct01282450)
J Thorac Oncol
Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients
Ann Oncol
Cited by (65)
Health-related quality of life in men with oligometastatic prostate cancer following metastases-directed stereotactic body radiotherapy: Real-world data from the E<sup>2</sup>-RADIatE OligoCare cohort
2024, Clinical and Translational Radiation OncologyDosimetric Analysis of Proximal Bronchial Tree Subsegments to Assess The Risk of Severe Toxicity After Stereotactic Body Radiation Therapy of Ultra-central Lung Tumors
2024, Clinical and Translational Radiation OncologyRadiotherapy in the management of lung oligometastases
2024, Cancer/RadiotherapieStereotactic Body Radiation Therapy for Oligoprogressive and Oligorecurrent Non–Small-Cell Lung Cancer
2023, Clinical Lung Cancer
Conflict of interest: none.